Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + zanzalintinib versus belzutifan + placebo in previously treated advanced renal cell carcinoma
2024-516993-31-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- May 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Belzutifan + zanzalintinib with Belzutifan + placebo (2 arms). Primary endpoints: Progression Free Survival and Overall Survival. Planned start May 2026; status: authorised.
02
Drugs
belzutifanzanzalintinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-516993-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516993-31-00.